Adults with heart-healthy metrics had better health from head to toe
Embargoed until 4 a.m. CT/5 a.m. ET, Wednesday, July 16, 2025
( NewMediaWire ) - July 16, 2025 - DALLAS — People who had more heart-healthy habits and factors, as assessed by the American Heart Association's Life's Simple 7(TM) metrics for ideal cardiovascular health, had more positive benefits for whole body health, according to a review of research published today in the Journal of the American Heart Association, an open-access, peer-reviewed journal of the American Heart Association.
Life's Simple 7 was launched by the American Heart Association in 2010 to define and quantify the spectrum of heart health based on seven lifestyle and health measures: not smoking, healthy nutrition, regular physical activity, healthy weight and normal blood pressure, cholesterol and blood sugar levels. In 2022, the metrics were refined to include sufficient sleep and more detailed scoring. The updated cardiovascular health metric is now called Life's Essential 8(TM).
While the cardiovascular benefits of optimal cardiovascular health in terms of Life's Simple 7 were already well-established, this is the first systematic review that examines the benefits to organs beyond the heart and death from cardiovascular disease and other causes, according to study authors.
'A few years ago, we learned that heart health and brain health are very closely tied. Through this review, we found that almost every organ system and bodily function also benefits from maintaining the healthy lifestyle behaviors of Life's Simple 7,' said lead study author Liliana Aguayo, Ph.D., M.P.H., a research assistant professor at the Nell Hodgson Woodruff School of Nursing and the Global Diabetes Research Center at Emory University in Atlanta. 'We were pleasantly surprised to find that Life's Simple 7 at optimal levels touched every aspect of health, from head to toe. It goes well beyond just cardiovascular health to encompass whole-body health.'
Researchers reviewed nearly 500 research studies published in the decade after Life's Simple 7 was introduced that had incorporated at least three of Life's Simple 7 measures. Ideal cardiovascular health was defined as having six or seven of the metrics at high levels.
Among the findings:
'These findings confirm that healthy lifestyle metrics — eating well, exercising and not smoking — are key components to optimal health, in addition to maintaining healthy weight, normal blood pressure, and cholesterol blood sugar levels, which are the conventional risk factors for cardiovascular disease,' Aguayo said.
'The ideal cardiovascular health metrics in Life's Simple 7 and now Life's Essential 8 are based on extensive scientific research that recognizes the majority of heart disease and stroke can be prevented,' said Stacey E. Rosen, M.D., FAHA, volunteer president of the American Heart Association and senior vice president of women's health and executive director of the Katz Institute for Women's Health of Northwell Health in New York City. 'The findings in this review study indicate that these healthy lifestyle metrics are also a path to improving health and well-being across the board, from head to toe. Preventing cardiovascular disease and reducing cardiovascular disease risk, the centerpieces for Life's Essential 8, are the core of the American Heart Association's mission to be a relentless force for a world of longer, healthier lives.'
The review findings are limited due to the scoring system of Life's Simple 7, which rates each category broadly as ideal, intermediate or poor and is less precise than is now possible under the methods of Life's Essential 8, according to Aguayo. Because this study relies on published literature, it may under-represent studies with negative or inconclusive findings, researchers said.
The investigators called for more research especially among children, pregnant women and populations in less-studied areas of the world. Also, more research is needed on both the benefits of even small improvements in these health metrics and the mechanisms that are pathways between Life's Simple 7 or Life's Essential 8 and better health.
Study details, background and design:
This review was partially funded by a Strategically Focused Research Network grant from
the American Heart Association as well as a grant from the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the American Heart Association. Co-authors and disclosures are listed in the manuscript.
Studies published in the American Heart Association's scientific journals are peer-reviewed. The statements and conclusions in each manuscript are solely those of the study authors and do not necessarily reflect the Association's policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content. Overall financial information is available here.
Additional Resources:
###
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173
Staff contact: [email protected]
For Public Inquiries: 1-800-AHA-USA1 (242-8721)
heart.org and stroke.org
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
12 hours ago
- Yahoo
Perseid meteor shower brings celestial fireballs to Tennessee. Here's the best time to view
With broiling temperatures during the day, maybe it's time to plan a cooler nighttime excursion. Say, watching the popular Perseid meteor shower? Backyard astronomers and stargazers can look to the night sky for the next several weeks to watch the prolific Perseid meteor shower. The celestial fire show started on July 17, but the meteor shower is almost a month long. "The Perseids, which peak in mid-August, are considered the best meteor shower of the year," according to NASA. "With swift and bright meteors, Perseids frequently leave long 'wakes' of light and color behind them as they streak through Earth's atmosphere." Usually, this fairly prolific celestial show is a fiery sight producing large, bright meteors during peak viewing, but for 2025 that light will be dimmed due to the moon. Here's what to know. When is the peak of the Perseid meteor shower? The Perseid meteor shower will peak on the night of Aug. 12 into the early morning of Aug. 13. How many meteors can be expected during Perseid's peak? People can expect to see 50 to 75 meteors per hour under ideal conditions during the peak, according to the American Meteor Society. The large, bright meteors, usually referred to as fireballs, won't be as spectacular this year due to how close the Perseid peak is to the August full moon. When is the next full moon? August's full moon, known as the Sturgeon moon, reaches peak at 3:55 a.m. ET/2:55 CT on Aug. 9. When is the best time to watch the Perseid meteor shower in Tennessee? Stargazers can catch the meteor shower between midnight and dawn, according to the society. The Perseid meteor shower can be seen anywhere with a clear sky and not a lot of light pollution. Considering the peak is just a few days after the full moon, a good day to have a great view happens on July 24. That's when the new moon rises, according to the Farmers' Almanac. If you are looking for a different experience, multiple Tennessee state parks are holding a couple of nighttime events for the peak of the meteor shower. You can find information on night hikes and viewing events across the Volunteer State. Some of the events do cost to participate. Night hike at Burgess Falls State Park Viewing at Burgess Falls State Park Kayak float at Old Fort When is the last night of the Perseid meteor shower? The Perseid meteor shower ends on Aug. 21 USA TODAY contributed to this story. This article originally appeared on Nashville Tennessean: Perseid meteor shower: Here's where, when to view celestial fireballs Solve the daily Crossword
Hamilton Spectator
13 hours ago
- Hamilton Spectator
Eupraxia Pharmaceuticals Invited to Present at Upcoming Investor Conferences
VICTORIA, British Columbia, July 22, 2025 (GLOBE NEWSWIRE) — Eupraxia Pharmaceuticals Inc. ('Eupraxia' or the 'Company') (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced that the Company's management team will present and participate at the following upcoming investor conferences: Canaccord Growth 45th Annual Growth Conference Date: August 12 - 14, 2025 Presentation date & time: August 13, 2025, 9:30am ET Location: Boston, MA Citi Biopharma Back to School Conference Date: September 2-3, 2025 Location: Boston, MA Cantor Global Healthcare Conference Date: September 3-5, 2025 Presentation date & time: September 5, 2025, 9:10am ET Location: New York, NY H.C. Wainwright 27th Annual Global Investment Conference Date: September 8-10, 2025 Location: New York, NY About Eupraxia Pharmaceuticals Inc. Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere™, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The technology is designed to support extended duration of effect and delivery of drugs in a hyper-localized fashion, targeting only the tissues that physicians are wanting to treat. We believe the potential for fewer adverse events may be achieved through the precision targeting and the stable and flat delivery of the active ingredient when using the DiffuSphere™ technology, versus the peaks and troughs seen with more traditional drug delivery methods. The precision of Eupraxia's DiffuSphere™ technology platform has the potential to augment and transform existing FDA-approved drugs to improve their safety, tolerability, efficacy and duration of effect. The potential uses in therapeutic areas may go beyond pain and inflammatory gastrointestinal disease, where Eupraxia currently is developing advanced treatments, to also be applicable in oncology, infectious disease and other critical disease areas. Eupraxia's EP-104GI is currently in a Phase 1b/2 trial, the RESOLVE trial, for the treatment of EoE. EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. This is a unique treatment approach for EoE. Eupraxia also recently completed a Phase 2b clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. The trial met its primary endpoint and three of the four secondary endpoints. In addition, Eupraxia is developing a pipeline of later and earlier-stage long-acting formulations. Potential pipeline indications include candidates for other inflammatory joint indications and oncology, each designed to improve on the activity and tolerability of currently approved drugs. For further details about Eupraxia, please visit the Company's website at: . Notice Regarding Forward-looking Statements and Information This news release includes forward-looking statements and forward-looking information within the meaning of applicable securities laws. Often, but not always, forward-looking information can be identified by the use of words such as 'plans', 'is expected', 'expects', 'suggests', 'scheduled', 'intends', 'contemplates', 'anticipates', 'believes', 'proposes', 'potential' or variations (including negative and grammatical variations) of such words and phrases, or state that certain actions, events or results 'may', 'could', 'would', 'might' or 'will' be taken, occur or be achieved. Forward-looking statements in this news release include statements regarding the expected enrollment and number of sites for the Phase 2b portion of the RESOLVE study; the expected parameters of the RESOLVE study; the availability of topline data and release of additional long-term data with higher doses and timing thereof; the Company's product candidates, including their expected benefits to patients with respect to safety, tolerability, efficacy and duration; the expectations around proceeding to clinical trials for the Company's product candidates; the results gathered from studies and trials of Eupraxia's product candidates; the potential for the Company's technology to impact the drug delivery process; potential market opportunity for the Company's product candidates; and potential pipeline indications. Such statements and information are based on the current expectations of Eupraxia's management, and are based on assumptions, including but not limited to: future research and development plans for the Company proceeding substantially as currently envisioned; industry growth trends, including with respect to projected and actual industry sales; the Company's ability to obtain positive results from the Company's research and development activities, including clinical trials; and the Company's ability to protect patents and proprietary rights. Although Eupraxia's management believes that the assumptions underlying these statements and information are reasonable, they may prove to be incorrect. The forward-looking events and circumstances discussed in this news release may not occur by certain dates or at all and could differ materially as a result of known and unknown risk factors and uncertainties affecting Eupraxia, including, but not limited to: risks and uncertainties related to the Company's limited operating history; the Company's novel technology with uncertain market acceptance; if the Company breaches any of the agreements under which it licenses rights to its product candidates or technology from third parties, the Company could lose license rights that are important to its business; the Company's current license agreement may not provide an adequate remedy for its breach by the licensor; the Company's technology may not be successful for its intended use; the Company's future technology will require regulatory approval, which is costly and the Company may not be able to obtain it; the Company may fail to obtain regulatory approvals or only obtain approvals for limited uses or indications; the Company's clinical trials may fail to demonstrate adequately the safety and efficacy of its product candidates at any stage of clinical development; the Company may be required to suspend or discontinue clinical trials due to side effects or other safety risks; the Company completely relies on third parties to provide supplies and inputs required for its product candidates and services; the potential impact of tariffs on the cost of the Company's active pharmaceutical ingredients and clinical supplies of EP-104IAR and EP-104GI; the Company relies on external contract research organizations to provide clinical and non-clinical research services; the Company may not be able to successfully execute its business strategy; the Company will require additional financing, which may not be available; any therapeutics the Company develops will be subject to extensive, lengthy and uncertain regulatory requirements, which could adversely affect the Company's ability to obtain regulatory approval in a timely manner, or at all; the impact of health pandemics or epidemics on the Company's operations; the Company's restatement of its consolidated financial statements, which may lead to additional risks and uncertainties, including loss of investor confidence and negative impacts on the Company's common share price; and other risks and uncertainties described in more detail in Eupraxia's public filings on SEDAR+ ( and EDGAR ( Although Eupraxia has attempted to identify important factors that could cause actual actions, events or results to differ materially from those described in forward-looking statements and information, there may be other factors that cause actions, events or results to differ from those anticipated, estimated or intended. No forward-looking statement or information can be guaranteed. Except as required by applicable securities laws, forward-looking statements and information speak only as of the date on which they are made and Eupraxia undertakes no obligation to publicly update or revise any forward-looking statement or information, whether as a result of new information, future events or otherwise. For investor and media inquiries, please contact: Danielle Egan, Eupraxia Pharmaceuticals Inc. 778.401.3302 degan@ or Kevin Gardner, on behalf of: Eupraxia Pharmaceuticals Inc. 617.283.2856 kgardner@ SOURCE Eupraxia Pharmaceuticals Inc.
Associated Press
19 hours ago
- Associated Press
Startups chosen to drive technology-driven improvements in women s heart and brain health
( NewMediaWire ) - July 22, 2025 - DALLAS — In a collaboration between American Heart Association Ventures(TM) and the Association's Center for Health Technology and Innovation, eight companies have been selected to participate in the American Heart Association Heart and Brain Health Accelerator. Through the Accelerator, the American Heart Association, a global force changing the future of health for all, aims to drive innovation with the potential to enhance patient outcomes, lower costs and reduce barriers to care. This is one of many ways the Association is exploring cutting-edge technology solutions that are scalable, accessible and effective, ensuring that everyone, everywhere can live longer, healthier lives. 'Innovation is essential to advancing health and improving outcomes for people affected by heart disease and stroke,' said Lisa Suennen, managing partner of American Heart Association Ventures. 'Through the Heart and Brain Health Accelerator, we're proud to support breakthrough technologies with the potential to transform care. By connecting these companies to mentorship, funding and our network of experts, we aim to accelerate their path from promising concept to lifesaving impact.' The Heart Association's Heart and Brain Health Accelerator is one track within the larger MedTech Innovator Accelerator Program. The track is designed to identify and support companies with novel medical or digital health technologies aligned with the lifesaving mission of the American Heart Association. These eight finalists have specific solutions and applications identified by experts for their potential to positively impact women's cardiovascular and brain health outcomes: The selected health tech companies now also become official members of the Medtech Innovator program for this year, which includes access to networking opportunities, funding and increased visibility within the medical technology industry. In addition, they will receive specialized mentorship, coaching and capacity building from American Heart Association Ventures, customized to their focus on cardiovascular and/or brain conditions and diseases. As participants in the Heart and Brain Health Accelerator, these companies qualify to participate in the MedTech Innovator Competition Finals, held at the MedTech Conference on October 5-8, 2025, in San Diego. Astellas Rx+ sponsors the American Heart Association Heart and Brain Heath Accelerator track. The companies were selected by expert volunteers on an American Heart Association advisory committee, including: Additional Resources: ### About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public's health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on Facebook, X or by calling 1-800-AHA-USA1. For Media Inquiries: 214-706-1173 Michelle Rosenfeld: [email protected] For Public Inquiries: 1-800-AHA-USA1 (242-8721) and
